Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07639255 · ClinicalTrials.gov registry record · NA
Kentucky - Quality Improvement Implementation Lung Cancer Screening (QUILS™) Implementation
A NA study, sponsored by Timothy Mullett.
- Recruiting
- Registry status
- NA
- Development phase
- 330
- Enrollment target
NCT07639255: Recruiting NA study, sponsored by Timothy Mullett.
NCT07639255 is a NA study that is actively recruiting participants, run by Timothy Mullett. The registered enrollment target is 330 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07639255, a NA study, is actively recruiting participants, sponsored by Timothy Mullett.
- RECRUITING
- Registry status
- NA
- Development phase
- 330 participants
- Enrollment target
Study Summary
This is an optimization pathway for lung cancer screening programs. Enrolled programs will undergo an audit for elements associated with improved quality and retention of patients in the screening process. A feedback report is delivered to identify priorities for process improvement.
Primary Outcome
The QUILS Index Assessment is a program-level measure of lung cancer screening implementation quality. Scores range from 0 to 95, with a higher score indicating higher quality implementation of lung cancer screening practices. The outcome measure is the change in total QUILS Index score from Baseline to 12 months.
Interventions
- OTHER QUILS System
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 330 participants |
| Start Date | 2025-04-01 |
| Est. Completion | 2028-06-01 |
| Phase | NA |
What NCT07639255 shows while recruiting
NCT07639255 is an interventional study that assigns participants to a tested intervention. The registered 330 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (76% lower).
The record links to 0 conditions, and to 1 intervention - of which QUILS System is the first listed.
NCT07639255 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07639255 about?
NCT07639255 is a clinical study titled "Kentucky - Quality Improvement Implementation Lung Cancer Screening (QUILS™) Implementation". This is an optimization pathway for lung cancer screening programs. Enrolled programs will undergo an audit for elements associated with improved quality and retention of patients in the screening process. A feedback report is delivered to identify priorities for process improvement.
What is the current status of trial NCT07639255?
This trial is currently recruiting. It is a NA study. The enrollment target is 330 participants. The study started on 2025-04-01. Estimated completion is 2028-06-01.
What interventions are being tested in trial NCT07639255?
The interventions under investigation include: QUILS System (OTHER).
Who is sponsoring clinical trial NCT07639255?
This trial is sponsored by Timothy Mullett, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07639255's enrollment target sits among peer trials
330 307th of 2000 higher than 1,693 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00359684 · 330 participants
Use of Cysteamine in the Treatment of Cystinosis
- NCT03817502 · 330 participants · Phase 3
Efficacy and Safety of Cariprazine in the Treatment of Adolescent Participants (13 to 17 Years of Age) With Schizophrenia
- NCT03922724 · 330 participants · Phase 2
Allogeneic Hematopoietic Cell Transplantation for Peripheral T Cell Lymphoma
- NCT03932773 · 330 participants · NA
Multi-site Confirmatory Efficacy Treatment Trial of Combat-related PTSD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI